Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$4.34
0.061.40%
Pre-Market: 9:22 AM EDT
Comments
Loading...
Skye Bioscience (SKYE) Forecast
NewsEarningsSkye Bioscience (SKYE) OptionsGuidanceDividendsAnalyst RatingsInsider TradesShort InterestOverview Rating
Speculative
Skye Bioscience (NASDAQ:SKYE) Stock Quotes, Forecast and News Summary
Skye Bioscience Stock (NASDAQ: SKYE) stock price, news, charts, stock research, profile.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy Skye Bioscience (SKYE) stock?
You can purchase shares of Skye Bioscience (NASDAQ:SKYE) through any online brokerage.
Who are Skye Bioscience (SKYE) competitors?
Other companies in Skye Bioscience’s space includes: Outlook Therapeutics (NASDAQ:OTLK), Cabaletta Bio (NASDAQ:CABA), Innate Pharma (NASDAQ:IPHA), Adverum Biotechnologies (NASDAQ:ADVM) and PepGen (NASDAQ:PEPG).
What is the forecast, or price target, for Skye Bioscience (SKYE) stock?
Skye Bioscience has a consensus price target of $18.67.
What is the current price for Skye Bioscience (SKYE)?
The stock price for Skye Bioscience (NASDAQ: SKYE) is $4.34 last updated November 20, 2024 at 9:22 AM EST.
Does Skye Bioscience (SKYE) pay a dividend?
There are no upcoming dividends for Skye Bioscience.
When is Skye Bioscience (NASDAQ:SKYE) reporting earnings?
Skye Bioscience’s Q4 earnings are confirmed for Sunday, February 9, 2025.
Is Skye Bioscience (SKYE) going to split?
There is no upcoming split for Skye Bioscience.
What sector and industry does Skye Bioscience (SKYE) operate in?
Skye Bioscience is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.